Sitemap

Oxford Covid Vaccine Works In All Ages, Trials Suggest

Serbia Exported 30,000 Tons Of Ice Cream Worth 63.5 Million Euros

Last year, 30,000 tons of ice cream...

Italy Is Suing Slovenia Over Balsamic Vinegar

The Italian government is launching legal proceedings...

Ambassador Pinter: Serbia The Most Important Partner In Western Balkans

Hungary sees Serbia as the most important...

EU Governments: Recommendations On How To Save Energy

After it was published in the EU's...

Ambassador Christopher Hill: We Want Serbia As Friend And Ally

The Ambassador of the United States of America in Belgrade, H.E. Christopher Hill, answered the questions that citizens asked...

Swiss Army Airlifts Water To Thirsty Animals In Alpine Meadows

Swiss Army helicopters have been deployed to deliver water to thousands of thirsty farm animals during the hot summer. A...

Record Number Of Serbian Tourists Vacation In Croatia

This year the number of guests from Serbia spending their summer vacationing in Croatia is 60 percent higher than...

Ambassador Giorgos Diakofotakis: Greece is not changing its position, will not recognize Kosovo

Greece is not changing its position and will not recognize Kosovo, says Greek Ambassador to Serbia H.E. Giorgos Diakofotakis...

Belgrade Zoo Is Home To The Oldest Living American Alligator

85 years ago, on 9th August 1937, the oldest living American alligator in the world arrived at the Belgrade...

Covid vaccine being trialled by Oxford University and AstraZeneca offers hope for all age groups

One of the world’s leading Covid-19 experimental vaccines produces an immune response in older adults as well as the young, its developers say, raising hopes of protection for those most vulnerable to the coronavirus that has caused social and economic chaos around the world.

Neither Oxford University nor its commercial partner AstraZeneca would release the data from the early trials showing the positive effects, which are being submitted to a peer-reviewed journal. But AstraZeneca confirmed the basic findings about the vaccine it calls AZD1222, which were shared at a closed academic meeting.

The phase 2 trials have shown that people over the age of 56 – and some over 70 – produced the same sort of antibody response as younger volunteers. Whether older people would be protected has always been a key question for the vaccines being developed. The body’s natural immune system and therefore its ability to fight any virus weakens with age, which is why the Covid death rate rises in older people.

The data also shows that fewer side-effects – referred to by the scientists as “reactogenicity” – were reported in the older volunteers, which is encouraging, although it could mean fewer of them reported issues such as a sore arm.

“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222,” said an AstraZeneca spokesman.

A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. However, few think the first vaccines will be fully protective. They may instead reduce the severity of illness, so that people avoid hospital and deaths are reduced. They may also not last, so that boosters will be needed.

The data also shows that fewer side-effects – referred to by the scientists as “reactogenicity” – were reported in the older volunteers, which is encouraging, although it could mean fewer of them reported issues such as a sore arm.

“It is encouraging to see immunogenicity responses were similar between older and younger adults and that reactogenicity was lower in older adults, where the Covid-19 disease severity is higher. The results further build the body of evidence for the safety and immunogenicity of AZD1222,” said an AstraZeneca spokesman.

A vaccine that works is seen as a game-changer in the battle against coronavirus, which has killed more than 1.15 million people, shuttered swathes of the global economy and turned normal life upside down for billions of people. However, few think the first vaccines will be fully protective. They may instead reduce the severity of illness, so that people avoid hospital and deaths are reduced. They may also not last, so that boosters will be needed.

However, most experts outside the company, and the UK health secretary, Matt Hancock, expect it not to be available until 2021. Asked if some people could receive a vaccine this year, Hancock told the BBC: “I don’t rule that out but that is not my central expectation.”

Related

Russia

Testing Coronavirus Vaccine Prototypes on Animals

Russian scientists have begun testing prototypes of potential vaccines against the coronavirus on animals in a laboratory in Siberia, it was said in a...

Ksenija Purković, Country Director at AstraZeneca, Serbia

Health Sector According to The Nordic Recipe

Apart from the financial aspect, AstraZeneca can contribute greatly to developing or implementing procedures and processes in the healthcare sector with best practices shared...

Advertisement

Hancock said a vaccine was not yet ready but he was preparing logistics for a possible rollout, mostly in the first half of 2021. AstraZeneca has committed to mass manufacturing and has a capacity of 3bn doses – which equates to enough for 1.5 billion people globally getting the two-dose vaccine. It has also signed deals with manufacturers in other countries, such as India.

The final trials (phase 3), looking to see a significant difference in the numbers of deaths between those vaccinated and those who are not, are taking place in six countries. Trials in the US, which were paused after a volunteer in the UK became ill, have resumed. The other countries participating are South Africa, Brazil, Japan and India.

The vaccine is expected to be one of the first from big pharma to secure regulatory approval, along with one from Pfizer and BioNTech.

Work began on the Oxford vaccine in January. Called AZD1222 or ChAdOx1 nCoV-19, the viral-vector vaccine is made from a weakened version of a common cold virus that causes infections in chimpanzees.

Stephen Evans, a professor of pharmacoepidemiology at the London School of Hygiene & Tropical Medicine, cautioned that no conclusions about the efficacy of the vaccine should be drawn until the data had been published.

“In order to comment properly on this we need to see the data,” he said. “It is encouraging that the investigators suggest that the immune responses measured in the blood seem to show efficacy both above, as well as below, age 70. The later phase trials are needed to see if the immune responses translate into clinical efficacy in preventing infection. These will involve much larger numbers and it is wise to not be too optimistic until those trials have completed.” Raised antibody levels in the blood indicated but did not guarantee protection from the virus multiplying in the body, he said.

Source: theguardian.com

Related Articles

EU To Extend Digital Covid Certificate For Travel Until June 2023

As the current EU Digital Covid Certificate rules are set to expire on 30 June, the Committee on Civil Liberties, Justice and Home Affairs...

WHO: Three Possible Scenarios For The Pandemic

The World Health Organization (WHO) has released an updated plan for Covid-19, describing three possible scenarios for how the pandemic may develop by the...

Anti-Vaccine Activists March In D.C. – City That Mandates Coronavirus Vaccination – To Protest Mandates

Thousands of protesters from across the country — including some of the biggest names in the anti-vaccination movement — descended on the nation’s capital Sunday for...

US Supreme Court Blocks Biden’s Workplace Vaccine Mandate

The US Supreme Court has blocked President Joe Biden's rule requiring workers at large companies to be vaccinated or masked and tested weekly. The justices...

Protests Against Covid Rules And Lockdowns Erupt Across Europe

Protests against fresh Covid-19 restrictions have rocked Europe over the weekend, with demonstrations breaking out in places such as Brussels, Vienna, Rome and Amsterdam. There...

Fauci: COVID-19 Hospitalizations Rising Among Vaccinated

COVID-19 hospitalizations are rising among people who are fully vaccinated, according to Dr. Anthony Fauci, the director of the National Institute for Allergy and Infectious Disease.  Fauci discussed what was...

Serbia To Be Connected To The EU Digital COVID Certificate System

As of 16 November 2021, Serbia will be connected to the EU Digital COVID Certificate System. Being part of the EU’s Digital COVID Certificate System...

U.S. To Lift Restrictions Nov 8 For Vaccinated Foreign Travelers

The White House will lift COVID-19 travel restrictions for fully vaccinated international visitors starting Nov. 8, ending historic restrictions that had barred much of...